Chapter 1. Preface

1.1 Report Description and Scope
1.2 Research scope
1.3 Research methodology
1.3.1 Market Research Type
1.3.2 Market research methodology

Chapter 2. Executive Summary

2.1 Global Psychedelic Drugs Market, (2025 - 2034) (USD Billion)
2.2 Global Psychedelic Drugs Market: Snapshot

Chapter 3. Global Psychedelic Drugs Market - Industry Analysis

3.1 Psychedelic Drugs Market: Market Dynamics
3.2 Market Drivers
3.2.1 The growth of the psychedelic drugs market is primarily driven by the escalating global mental health crisis and the high failure rate of traditional antidepressants, which—bolstered by FDA Breakthrough Therapy designations for psilocybin and MDMA and over $3 billion in venture capital—are fueling a transition toward clinically validated, evidence-based psychedelic medicine.
3.3 Market Restraints
3.3.1 The growth of the psychedelic drugs market is primarily restrained by Schedule I regulatory restrictions that impose onerous research barriers and high operational costs, alongside specialized therapy requirements that hinder scalability and create a "pricing wall" for patients in 2026.
3.4 Market Opportunities
3.4.1 The growth of the psychedelic drugs market is primarily driven by the expansion of therapeutic indications into chronic pain and neurodegenerative diseases (like Alzheimer’s), which—combined with high-profile pharma-biotech partnerships and the integration of digital therapeutics like VR-assisted therapy—enable scalable, personalized care models across emerging markets in 2026.
3.5 Market Challenges
3.5.1 The growth of the psychedelic drugs market is primarily challenged by manufacturing complexities in maintaining dosing consistency and fragile IP positions on natural compounds, which, combined with a severe shortage of trained therapists and lack of standardized insurance reimbursement, impede the scalability of clinical-grade treatments in 2026.
3.6 Porter’s Five Forces Analysis
3.7 Market Attractiveness Analysis
3.7.1 Market attractiveness analysis By Drug Type
3.7.2 Market attractiveness analysis By Application
3.7.3 Market attractiveness analysis By Distribution Channel

Chapter 4. Global Psychedelic Drugs Market- Competitive Landscape

4.1 Company market share analysis
4.1.1 Global Psychedelic Drugs Market: company market share, 2024
4.2 Strategic development
4.2.1 Acquisitions & mergers
4.2.2 New Product launches
4.2.3 Agreements, partnerships, cullaborations, and joint ventures
4.2.4 Research and development and Regional expansion
4.3 Price trend analysis

Chapter 5. Global Psychedelic Drugs Market - Drug Type Analysis

5.1 Global Psychedelic Drugs Market Overview: Drug Type
5.1.1 Global Psychedelic Drugs Market share, By Drug Type, 2024 and 2034
5.2 Psilocybin
5.2.1 Global Psychedelic Drugs Market by Psilocybin, 2025 - 2034 (USD Billion)
5.3 LSD
5.3.1 Global Psychedelic Drugs Market by LSD, 2025 - 2034 (USD Billion)
5.4 MDMA
5.4.1 Global Psychedelic Drugs Market by MDMA, 2025 - 2034 (USD Billion)
5.5 Ketamine
5.5.1 Global Psychedelic Drugs Market by Ketamine, 2025 - 2034 (USD Billion)
5.6 Ayahuasca
5.6.1 Global Psychedelic Drugs Market by Ayahuasca, 2025 - 2034 (USD Billion)
5.7 DMT
5.7.1 Global Psychedelic Drugs Market by DMT, 2025 - 2034 (USD Billion)
5.8 Ibogaine
5.8.1 Global Psychedelic Drugs Market by Ibogaine, 2025 - 2034 (USD Billion)
5.9 Salvinorin A
5.9.1 Global Psychedelic Drugs Market by Salvinorin A, 2025 - 2034 (USD Billion)
5.10 Mescaline
5.10.1 Global Psychedelic Drugs Market by Mescaline, 2025 - 2034 (USD Billion)
5.11 2C-B
5.11.1 Global Psychedelic Drugs Market by 2C-B, 2025 - 2034 (USD Billion)

Chapter 6. Global Psychedelic Drugs Market - Application Analysis

6.1 Global Psychedelic Drugs Market Overview: Application
6.1.1 Global Psychedelic Drugs Market share, By Application, 2024 and 2034
6.2 Depression
6.2.1 Global Psychedelic Drugs Market by Depression, 2025 - 2034 (USD Billion)
6.3 PTSD
6.3.1 Global Psychedelic Drugs Market by PTSD, 2025 - 2034 (USD Billion)
6.4 Anxiety Disorders
6.4.1 Global Psychedelic Drugs Market by Anxiety Disorders, 2025 - 2034 (USD Billion)
6.5 Addiction Treatment
6.5.1 Global Psychedelic Drugs Market by Addiction Treatment, 2025 - 2034 (USD Billion)
6.6 Pain Management
6.6.1 Global Psychedelic Drugs Market by Pain Management, 2025 - 2034 (USD Billion)
6.7 Cluster Headaches
6.7.1 Global Psychedelic Drugs Market by Cluster Headaches, 2025 - 2034 (USD Billion)
6.8 OCD
6.8.1 Global Psychedelic Drugs Market by OCD, 2025 - 2034 (USD Billion)
6.9 Eating Disorders
6.9.1 Global Psychedelic Drugs Market by Eating Disorders, 2025 - 2034 (USD Billion)
6.10 Bipolar Disorder
6.10.1 Global Psychedelic Drugs Market by Bipolar Disorder, 2025 - 2034 (USD Billion)
6.11 Schizophrenia
6.11.1 Global Psychedelic Drugs Market by Schizophrenia, 2025 - 2034 (USD Billion)

Chapter 7. Global Psychedelic Drugs Market - Distribution Channel Analysis

7.1 Global Psychedelic Drugs Market Overview: Distribution Channel
7.1.1 Global Psychedelic Drugs Market share, By Distribution Channel, 2024 and 2034
7.2 Hospitals Pharmacies
7.2.1 Global Psychedelic Drugs Market by Hospitals Pharmacies, 2025 - 2034 (USD Billion)
7.3 Retail Pharmacies
7.3.1 Global Psychedelic Drugs Market by Retail Pharmacies, 2025 - 2034 (USD Billion)
7.4 Online Pharmacies
7.4.1 Global Psychedelic Drugs Market by Online Pharmacies, 2025 - 2034 (USD Billion)
7.5 Clinics
7.5.1 Global Psychedelic Drugs Market by Clinics, 2025 - 2034 (USD Billion)
7.6 Research Centers
7.6.1 Global Psychedelic Drugs Market by Research Centers, 2025 - 2034 (USD Billion)
7.7 Specialty Stores
7.7.1 Global Psychedelic Drugs Market by Specialty Stores, 2025 - 2034 (USD Billion)
7.8 Compounding Pharmacies
7.8.1 Global Psychedelic Drugs Market by Compounding Pharmacies, 2025 - 2034 (USD Billion)
7.9 Mail Order Pharmacies
7.9.1 Global Psychedelic Drugs Market by Mail Order Pharmacies, 2025 - 2034 (USD Billion)
7.10 Institutional Sales
7.10.1 Global Psychedelic Drugs Market by Institutional Sales, 2025 - 2034 (USD Billion)
7.11 Direct Sales
7.11.1 Global Psychedelic Drugs Market by Direct Sales, 2025 - 2034 (USD Billion)

Chapter 8. Psychedelic Drugs Market - Regional Analysis

8.1 Global Psychedelic Drugs Market Regional Overview
8.2 Global Psychedelic Drugs Market Share, by Region, 2024 & 2034 (USD Billion)
8.3 North America
8.3.1 North America Psychedelic Drugs Market, 2025 - 2034 (USD Billion)
8.3.1.1 North America Psychedelic Drugs Market, by Country, 2025 - 2034 (USD Billion)
8.3.2 North America Psychedelic Drugs Market, by Drug Type, 2025 - 2034
8.3.2.1 North America Psychedelic Drugs Market, by Drug Type, 2025 - 2034 (USD Billion)
8.3.3 North America Psychedelic Drugs Market, by Application, 2025 - 2034
8.3.3.1 North America Psychedelic Drugs Market, by Application, 2025 - 2034 (USD Billion)
8.3.4 North America Psychedelic Drugs Market, by Distribution Channel, 2025 - 2034
8.3.4.1 North America Psychedelic Drugs Market, by Distribution Channel, 2025 - 2034 (USD Billion)
8.4 Europe
8.4.1 Europe Psychedelic Drugs Market, 2025 - 2034 (USD Billion)
8.4.1.1 Europe Psychedelic Drugs Market, by Country, 2025 - 2034 (USD Billion)
8.4.2 Europe Psychedelic Drugs Market, by Drug Type, 2025 - 2034
8.4.2.1 Europe Psychedelic Drugs Market, by Drug Type, 2025 - 2034 (USD Billion)
8.4.3 Europe Psychedelic Drugs Market, by Application, 2025 - 2034
8.4.3.1 Europe Psychedelic Drugs Market, by Application, 2025 - 2034 (USD Billion)
8.4.4 Europe Psychedelic Drugs Market, by Distribution Channel, 2025 - 2034
8.4.4.1 Europe Psychedelic Drugs Market, by Distribution Channel, 2025 - 2034 (USD Billion)
8.5 Asia Pacific
8.5.1 Asia Pacific Psychedelic Drugs Market, 2025 - 2034 (USD Billion)
8.5.1.1 Asia Pacific Psychedelic Drugs Market, by Country, 2025 - 2034 (USD Billion)
8.5.2 Asia Pacific Psychedelic Drugs Market, by Drug Type, 2025 - 2034
8.5.2.1 Asia Pacific Psychedelic Drugs Market, by Drug Type, 2025 - 2034 (USD Billion)
8.5.3 Asia Pacific Psychedelic Drugs Market, by Application, 2025 - 2034
8.5.3.1 Asia Pacific Psychedelic Drugs Market, by Application, 2025 - 2034 (USD Billion)
8.5.4 Asia Pacific Psychedelic Drugs Market, by Distribution Channel, 2025 - 2034
8.5.4.1 Asia Pacific Psychedelic Drugs Market, by Distribution Channel, 2025 - 2034 (USD Billion)
8.6 Latin America
8.6.1 Latin America Psychedelic Drugs Market, 2025 - 2034 (USD Billion)
8.6.1.1 Latin America Psychedelic Drugs Market, by Country, 2025 - 2034 (USD Billion)
8.6.2 Latin America Psychedelic Drugs Market, by Drug Type, 2025 - 2034
8.6.2.1 Latin America Psychedelic Drugs Market, by Drug Type, 2025 - 2034 (USD Billion)
8.6.3 Latin America Psychedelic Drugs Market, by Application, 2025 - 2034
8.6.3.1 Latin America Psychedelic Drugs Market, by Application, 2025 - 2034 (USD Billion)
8.6.4 Latin America Psychedelic Drugs Market, by Distribution Channel, 2025 - 2034
8.6.4.1 Latin America Psychedelic Drugs Market, by Distribution Channel, 2025 - 2034 (USD Billion)
8.7 The Middle-East and Africa
8.7.1 The Middle-East and Africa Psychedelic Drugs Market, 2025 - 2034 (USD Billion)
8.7.1.1 The Middle-East and Africa Psychedelic Drugs Market, by Country, 2025 - 2034 (USD Billion)
8.7.2 The Middle-East and Africa Psychedelic Drugs Market, by Drug Type, 2025 - 2034
8.7.2.1 The Middle-East and Africa Psychedelic Drugs Market, by Drug Type, 2025 - 2034 (USD Billion)
8.7.3 The Middle-East and Africa Psychedelic Drugs Market, by Application, 2025 - 2034
8.7.3.1 The Middle-East and Africa Psychedelic Drugs Market, by Application, 2025 - 2034 (USD Billion)
8.7.4 The Middle-East and Africa Psychedelic Drugs Market, by Distribution Channel, 2025 - 2034
8.7.4.1 The Middle-East and Africa Psychedelic Drugs Market, by Distribution Channel, 2025 - 2034 (USD Billion)

Chapter 9. Company Profiles

9.1 Compass Pathways
9.1.1 Overview
9.1.2 Financials
9.1.3 Product Portfolio
9.1.4 Business Strategy
9.1.5 Recent Developments
9.2 Atai Life Sciences
9.2.1 Overview
9.2.2 Financials
9.2.3 Product Portfolio
9.2.4 Business Strategy
9.2.5 Recent Developments
9.3 MindMed
9.3.1 Overview
9.3.2 Financials
9.3.3 Product Portfolio
9.3.4 Business Strategy
9.3.5 Recent Developments
9.4 Cybin Inc.
9.4.1 Overview
9.4.2 Financials
9.4.3 Product Portfolio
9.4.4 Business Strategy
9.4.5 Recent Developments
9.5 Field Trip Health
9.5.1 Overview
9.5.2 Financials
9.5.3 Product Portfolio
9.5.4 Business Strategy
9.5.5 Recent Developments
9.6 and Others.
9.6.1 Overview
9.6.2 Financials
9.6.3 Product Portfolio
9.6.4 Business Strategy
9.6.5 Recent Developments

Frequently Asked Questions

The Psychedelic Drugs Market involves therapeutic substances like psilocybin and MDMA used for mental health treatments under medical supervision.

Key factors include regulatory approvals, clinical trial advancements, mental health awareness, and investment in biotech.

The market is projected to grow from USD 3.2 billion in 2026 to USD 13 billion by 2035.

The CAGR is expected to be 15%.

North America will contribute notably, driven by US regulatory progress.

Major players include Compass Pathways, Atai Life Sciences, MindMed, Cybin Inc., and Field Trip Health.

The report provides analysis of size, trends, segments, regions, players, and forecasts.

Stages include raw material sourcing, drug synthesis, clinical trials, regulatory approval, distribution, and therapy administration.

Trends shift toward personalized therapies, with consumers favoring evidence-based treatments for mental health.

Factors include decriminalization laws and ethical sourcing of natural psychedelics promoting sustainable growth.